This is a snippet of the transcript, sign up to read more.
It depends on how it's positioned. I wasn't part of those discussions. My role at Zoetis was strictly on the diagnostic side, trying to expand the diagnostic portfolio. I wasn't involved in conversations about positioning pharmaceuticals alongside diagnostics. What I do know is that in the first year, there was a significant leakage of diagnostic business away from Zoetis to IDEXX. They lost many customers because the focus remained on pharmaceuticals rather than diagnostics. This happened back in 2019 and 2020.
This is a snippet of the transcript, sign up to read more.
You need to provide an offering that allows the customer to conduct testing in their preferred manner, not dictated by you. If the customer wants immediate results on-site or prefers to send it out, they should have that option. Zoetis has invested in some reference labs, but IDEXX has local reference labs everywhere, allowing for same-day turnaround for basic blood results. This doesn't work for Zoetis, as they have to ship blood to regional labs. While Zoetis has entered that marketplace, they are not competing at the same level as Antech or IDEXX in the laboratory business. They lack the infrastructure that those two companies have.
This is a snippet of the transcript, sign up to read more.
IDEXX offers a much broader range of point-of-care panels than Zoetis does today, especially in chemistry.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.
Subscribe to access hundreds of interviews and primary research